FDA-cleared profile

qCT LN Quant

Qure.ai Technologies · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.

Clinical role
User-assisted semi-automatic nodule segmentation, measurement, and longitudinal comparison; results are informational, not diagnostic, and the clinician reviews and corrects the segmentation against the original images.
Images and patients
CT/CTA · Chest and lungs
Key limitation
Keep in mind: The device is not intended to diagnose disease or replace physician evaluation. Image noise and artifacts may reduce performance; use is not intended for idiopathic pulmonary fibrosis or extensive granulomatous disease or scans outside compatibility. Follow-up should use consistent CT parameters, and the clinician must verify or manually correct segmentation. Calculator and guideline outputs depend on user-entered information.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest and lungs Input: Non-contrast chest CT scans with user-selected or user-segmented solid pulmonary nodules at least 6 mm; DICOM input, received as de-identified scans through a modality or PACS.
  • Who uses it?Intended users: Radiologists and pulmonologists; certified medical specialists trained and experienced in reviewing and reporting chest CT.
  • What does the software produce?Output: Quantitative nodule average, long-axis, short-axis, and effective diameters, volume, mean/minimum/maximum HU, volume-doubling time, 2D/3D segmented views, Lung-RADS calculation, Brock Score risk calculation, and Fleischner-guideline-based reporting support.
  • What is its most important limitation?Key limitation: The device is not intended to diagnose disease or replace physician evaluation. Image noise and artifacts may reduce performance; use is not intended for idiopathic pulmonary fibrosis or extensive granulomatous disease or scans outside compatibility. Follow-up should use consistent CT parameters, and the clinician must verify or manually correct segmentation. Calculator and guideline outputs depend on user-entered information.

Clinical takeaway. Clinical role: Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.

Evidence takeaway. Evidence from the reviewed source record: FDA standalone clinical performance testing included 216 solid nodules from 118 chest CT scans of 104 subjects, with ground truth established by three expert radiologists. Median absolute normalized errors were 14.3% for short-axis diameter (95% CI 13.95%-16.67%), 11.1% for long-axis diameter (9.52%-12.50%), and 20.7% for volume (17.29%-22.41%). The packet describes these as quantitative measurement results against the reference standard and does not report diagnostic sensitivity or specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
User-assisted semi-automatic nodule segmentation, measurement, and longitudinal comparison; results are informational, not diagnostic, and the clinician reviews and corrects the segmentation against the original images.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Non-contrast chest CT scans with user-selected or user-segmented solid pulmonary nodules at least 6 mm; DICOM input, received as de-identified scans through a modality or PACS.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Quantitative nodule average, long-axis, short-axis, and effective diameters, volume, mean/minimum/maximum HU, volume-doubling time, 2D/3D segmented views, Lung-RADS calculation, Brock Score risk calculation, and Fleischner-guideline-based reporting support.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Chest CT and radiology workflow for single or serial thoracic studies.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Radiologists and pulmonologists; certified medical specialists trained and experienced in reviewing and reporting chest CT.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The device is not intended to diagnose disease or replace physician evaluation. Image noise and artifacts may reduce performance; use is not intended for idiopathic pulmonary fibrosis or extensive granulomatous disease or scans outside compatibility. Follow-up should use consistent CT parameters, and the clinician must verify or manually correct segmentation. Calculator and guideline outputs depend on user-entered information.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA standalone clinical performance testing included 216 solid nodules from 118 chest CT scans of 104 subjects, with ground truth established by three expert radiologists. Median absolute normalized errors were 14.3% for short-axis diameter (95% CI 13.95%-16.67%), 11.1% for long-axis diameter (9.52%-12.50%), and 20.7% for volume (17.29%-22.41%). The packet describes these as quantitative measurement results against the reference standard and does not report diagnostic sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA standalone clinical performance testing included 216 solid nodules from 118 chest CT scans of 104 subjects, with ground truth established by three expert radiologists. Median absolute normalized errors were 14.3% for short-axis diameter (95% CI 13.95%-16.67%), 11.1% for long-axis diameter (9.52%-12.50%), and 20.7% for volume (17.29%-22.41%). The packet describes these as quantitative measurement results against the reference standard and does not report diagnostic sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

qCT LN Quant regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240740
  • Samplen=104
  • IndependenceIndependence not established

K240740

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240740. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast chest CT scans with user-selected or user-segmented solid pulmonary nodules at least 6 mm; DICOM input, received as de-identified scans through a modality or PACS.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240740: qCT LN Quant

  2. Routing

    Source context, not route validation: A cloud module receives de-identified DICOM scans from a modality or PACS and returns results to the same destination. PACS mode uses a secondary-capture series with segmentation for PACS supporting GSPS output; web mode displays overlays in the Qure web application. Exact local interfaces and versions are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240740: qCT LN Quant

  3. AI processing

    Source context, not route validation: The exact FDA package describes qCT LN Quant as consisting of a cloud module that receives de-identified scans from a DICOM modality or PACS and returns results there, with a web-based mode showing segmentation on Qure's web application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "qCT LN Quant consists of a cloud module that can interacts with DICOM modality or the user’s picture archiving and communication system (PACS) to receive de-identified scans and returns the results to the same destination" … "Web-based mode: On Qure’s web application where the segmentation is overlaid on top of the original scan.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K240740: qCT LN Quant

  4. Returned objects

    Source context, not route validation: Quantitative nodule average, long-axis, short-axis, and effective diameters, volume, mean/minimum/maximum HU, volume-doubling time, 2D/3D segmented views, Lung-RADS calculation, Brock Score risk calculation, and Fleischner-guideline-based reporting support.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240740: qCT LN Quant

  5. Viewer/worklist/report

    Unresolved route: Quantitative nodule average, long-axis, short-axis, and effective diameters, volume, mean/minimum/maximum HU, volume-doubling time, 2D/3D segmented views, Lung-RADS calculation, Brock Score risk calculation, and Fleischner-guideline-based reporting support.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240740: qCT LN Quant

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes qCT LN Quant as consisting of a cloud module that receives de-identified scans from a DICOM modality or PACS and returns results there, with a web-based mode showing segmentation on Qure's web application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "qCT LN Quant consists of a cloud module that can interacts with DICOM modality or the user’s picture archiving and communication system (PACS) to receive de-identified scans and returns the results to the same destination" … "Web-based mode: On Qure’s web application where the segmentation is overlaid on top of the original scan.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
A cloud module receives de-identified DICOM scans from a modality or PACS and returns results to the same destination. PACS mode uses a secondary-capture series with segmentation for PACS supporting GSPS output; web mode displays overlays in the Qure web application. Exact local interfaces and versions are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Qure.ai's documentation FAQ says data is sent over HTTPS (TLS 1.2 or higher), stored encrypted at rest with AES-256-GCM, backed up with restore tests twice a year, and that Qure maintains an ISO 27001 certification with periodic surveillance audits. It also says hospitals anonymize PHI before sending data. The certificate itself was not read and no date or scope is given.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Monitoring
Qure.ai's vulnerability disclosure programme states that it covers all Qure.ai commercial products, including cloud-hosted products and Qure.ai-operated infrastructure, and commits to handling every report promptly and transparently with an acknowledgement and tracking reference within 2 business days.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Qure.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established. The programme is an intake and response-handling commitment; it makes no uptime, drift or continuous-monitoring claims.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for qCT LN Quant; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240740
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Chest and lungs
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-08-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240740 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA K240740: qCT LN Quant

    U.S. Food and Drug Administration - Published 2024-08-16 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. qCT LN Quant model card (K240740)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240740

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Qure.ai Documentation: Security and Privacy FAQ

    Qure.Ai Technologies - Accessed 2026-10-25

    Scope: security

  9. Qure.ai Vulnerability Disclosure Programme

    Qure.ai - Accessed 2026-10-27

    Scope: security, monitoring

Research history

  1. K240740 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K233753

AI-Rad Companion (Pulmonary)

Siemens Healthcare GmbH

Authorized purpose: AI-Rad Companion Pulmonary is image-processing software that provides quantitative and qualitative analysis from previously acquired CT DICOM images to support radiologists and physicians in evaluating and assessing lung disease. It segments and measures lungs, lobes, parenchyma, and solid or sub-solid nodules, identifies areas above or below specified Hounsfield-value thresholds, supports an external Lung CAD interface, associates nodules with lobes, and compares current nodules with known priors. Valid input is DICOM imaging of adult patients; the FDA summary identifies software version VA40.

Modality
CT/CTA
Anatomy
Adult lungs, lung lobes, pulmonary parenchyma, and solid or sub-solid lung nodules
Decision
2024-03-21
FDA-cleared K213713

AI-Rad Companion (Pulmonary)

Siemens Healthcare GmBh

AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2022-08-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history